US 12,441,779 B2
Plasmid combination and application thereof in preparing modified immune cells
Yun Liu, Tianjin (CN); Lin Shi, Tianjin (CN); Lulu Lv, Tianjin (CN); Pan Xie, Tianjin (CN); Mengmeng Cao, Tianjin (CN); Wang Yang, Tianjin (CN); Jiaxing Yang, Tianjin (CN); Fei Wang, Tianjin (CN); and Rui Wang, Tianjin (CN)
Assigned to JUVENTAS CELL THERAPY LTD., Tianjin (CN)
Filed by JUVENTAS CELL THERAPY LTD., Tianjin (CN)
Filed on Oct. 5, 2022, as Appl. No. 17/938,182.
Application 17/938,182 is a continuation of application No. 17/412,617, filed on Aug. 26, 2021, granted, now 11,497,771.
Application 17/412,617 is a continuation of application No. PCT/CN2020/136542, filed on Dec. 15, 2020.
Claims priority of application No. 201911301518.8 (CN), filed on Dec. 17, 2019; application No. 202011274810.8 (CN), filed on Nov. 16, 2020; and application No. 202011433671.9 (CN), filed on Dec. 10, 2020.
Prior Publication US 2023/0146337 A1, May 11, 2023
Int. Cl. A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/02 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01)
CPC C07K 14/70521 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61P 35/02 (2018.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 16/2887 (2013.01); C12N 5/0636 (2013.01); C12N 5/0646 (2013.01); C12N 15/86 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05)] 14 Claims
 
1. A method for treating a disease or disorder associated with CD19 expression, comprising administering, to a patient in need thereof,
a composition comprising a modified immune effector cell,
wherein the modified immune effector cell is prepared by a method comprising:
introducing a plasmid combination into a cell to prepare a lentiviral vector; wherein the plasmid combination comprises plasmids Seq1, PMD2.G, pMDLg-pRRE and pRSV-Rev present at a ratio of 3-6:1-1.5:1-3:1-1.5, wherein the plasmid Seq1 comprises a nucleic acid molecule encoding a chimeric antigen receptor comprising the amino acid sequence of SEQ ID NO. 1; and
introducing the lentiviral vector into an immune effector cell to prepare the modified immune effector cell.